Łukasz Kwinta

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
AIM OF THE STUDY The BRAF inhibitor vemurafenib has improved progression-free survival and overall survival in patients with BRAFV600-mutation-positive metastatic melanoma. Here we present the results of an open-label safety study with vemurafenib in patients with metastatic melanoma enrolled in Polish oncological centres. MATERIAL AND METHODS Patients(More)
  • 1